RxDoctor Payments Data

Paul Houlihan, MD

Interventional Cardiology · Edgewood, KYNPI 1164415907

Payments from drug & device makers

$10,548in general payments, 2019–2025

Across 562 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Abiomed$2K
  • Johnson & Johnson$1K
  • Abbott$824
  • Amgen$718
  • E.r. Squibb & Sons, L.L.C.$693
  • plus $4K from 30 others

What the payments were for

  • Travel & lodging$8738%
  • Food & beverage$9,64691%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,548 in reported general payments places this provider in the 50th percentile of 129 interventional cardiology providers in Kentucky.

See all interventional cardiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$182,219
Medicare patients
1,336
Services billed
2,622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban818$761,136
EntrestoSacubitril/Valsartan165$198,330
XareltoRivaroxaban159$165,503
FarxigaDapagliflozin Propanediol118$88,232
Repatha SureclickEvolocumab93$76,125
JardianceEmpagliflozin33$24,615
Repatha SyringeEvolocumab24$16,515
Praluent PenAlirocumab15$14,867
BrilintaTicagrelor22$14,417
Ranolazine ErRanolazine119$9,727
Metoprolol Succinate622$7,245
Atorvastatin Calcium702$5,462
VascepaIcosapent Ethyl13$5,021
Amiodarone Hcl88$4,977
Ezetimibe277$4,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$670$761,136818 claims
NovartisEntresto$1,674$198,330165 claims
Johnson & JohnsonXarelto$1,414$165,503159 claims
AstraZenecaFarxiga, Brilinta$351$102,649140 claims
Boehringer IngelheimJardiance$520$24,61533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 129 interventional cardiology providers in Kentucky.

Other interventional cardiology in Edgewood

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →